BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hait WN, Yang JM. Clinical management of recurrent breast cancer: development of multidrug resistance (MDR) and strategies to circumvent it. Semin Oncol. 2005;32:S16-21. [PMID: 16360718 DOI: 10.1053/j.seminoncol.2005.09.011] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.4] [Reference Citation Analysis]
Number Citing Articles
1 Liang X, Ji M, Liao Z, Zhao G, Tang X, Dong W. Chemosensitizing effect and mechanism of imperatorin on the anti-tumor activity of doxorubicin in tumor cells and transplantation tumor model. Korean J Physiol Pharmacol 2022;26:145-155. [DOI: 10.4196/kjpp.2022.26.3.145] [Reference Citation Analysis]
2 Du F, Yu L, Wu Y, Wang S, Yao J, Zheng X, Xie S, Zhang S, Lu X, Liu Y, Chen W. miR-137 alleviates doxorubicin resistance in breast cancer through inhibition of epithelial-mesenchymal transition by targeting DUSP4. Cell Death Dis 2019;10:922. [PMID: 31801953 DOI: 10.1038/s41419-019-2164-2] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 14.0] [Reference Citation Analysis]
3 Han B, Qu C, Park K, Konieczny SF, Korc M. Recapitulation of complex transport and action of drugs at the tumor microenvironment using tumor-microenvironment-on-chip. Cancer Lett 2016;380:319-29. [PMID: 26688098 DOI: 10.1016/j.canlet.2015.12.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
4 Arnason T, Harkness T. Development, Maintenance, and Reversal of Multiple Drug Resistance: At the Crossroads of TFPI1, ABC Transporters, and HIF1. Cancers (Basel) 2015;7:2063-82. [PMID: 26501324 DOI: 10.3390/cancers7040877] [Cited by in Crossref: 24] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
5 Wang PP, Xu DJ, Huang C, Wang WP, Xu WK. Astragaloside Ⅳ reduces the expression level of P-glycoprotein in multidrug-resistant human hepatic cancer cell lines. Mol Med Rep 2014;9:2131-7. [PMID: 24676670 DOI: 10.3892/mmr.2014.2074] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.6] [Reference Citation Analysis]
6 Fryknäs M, Gullbo J, Wang X, Rickardson L, Jarvius M, Wickström M, Hassan S, Andersson C, Gustafsson M, Westman G, Nygren P, Linder S, Larsson R. Screening for phenotype selective activity in multidrug resistant cells identifies a novel tubulin active agent insensitive to common forms of cancer drug resistance. BMC Cancer 2013;13:374. [PMID: 23919498 DOI: 10.1186/1471-2407-13-374] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
7 Dinarvand R, Varshochian R, Kamalinia G, Goodarzi N, Atyabi F. Recent approaches to overcoming multiple drug resistance in breast cancer using modified liposomes. Clinical Lipidology 2013;8:391-394. [DOI: 10.2217/clp.13.33] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
8 Su J, Lai H, Chen J, Li L, Wong YS, Chen T, Li X. Natural borneol, a monoterpenoid compound, potentiates selenocystine-induced apoptosis in human hepatocellular carcinoma cells by enhancement of cellular uptake and activation of ROS-mediated DNA damage. PLoS One. 2013;8:e63502. [PMID: 23700426 DOI: 10.1371/journal.pone.0063502] [Cited by in Crossref: 57] [Cited by in F6Publishing: 63] [Article Influence: 6.3] [Reference Citation Analysis]
9 Han B. Complex Transport Around Tumor: Need for Realistic In Vitro Tumor Transport Model. Cancer Targeted Drug Delivery 2013. [DOI: 10.1007/978-1-4614-7876-8_25] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
10 Huang C, Xu D, Xia Q, Wang P, Rong C, Su Y. Reversal of P-glycoprotein-mediated multidrug resistance of human hepatic cancer cells by Astragaloside II. J Pharm Pharmacol. 2012;64:1741-1750. [PMID: 23146037 DOI: 10.1111/j.2042-7158.2012.01549.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 52] [Article Influence: 5.1] [Reference Citation Analysis]
11 Ma B, Chai S, Li N, To KK, Kan WLT, Yang D, Lin G. Reversal of P-glycoprotein-mediated multidrug resistance by a synthetic α-aminoxy peptidomimetic. International Journal of Pharmaceutics 2012;424:33-9. [DOI: 10.1016/j.ijpharm.2011.12.046] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.7] [Reference Citation Analysis]
12 Huang C, Li Y, Cao P, Xie Z, Qin Z. Synergistic effect of hyperthermia and neferine on reverse multidrug resistance in adriamycin-resistant SGC7901/ADM gastric cancer cells. J Huazhong Univ Sci Technol [Med Sci ] 2011;31:488-96. [DOI: 10.1007/s11596-011-0478-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
13 Chen J, Lu L, feng Y, Wang H, Dai L, li Y, Zhang P. PKD2 mediates multi-drug resistance in breast cancer cells through modulation of P-glycoprotein expression. Cancer Letters 2011;300:48-56. [DOI: 10.1016/j.canlet.2010.09.005] [Cited by in Crossref: 58] [Cited by in F6Publishing: 62] [Article Influence: 5.3] [Reference Citation Analysis]
14 Patwardhan G, Gupta V, Huang J, Gu X, Liu YY. Direct assessment of P-glycoprotein efflux to determine tumor response to chemotherapy. Biochem Pharmacol 2010;80:72-9. [PMID: 20298675 DOI: 10.1016/j.bcp.2010.03.010] [Cited by in Crossref: 18] [Cited by in F6Publishing: 23] [Article Influence: 1.5] [Reference Citation Analysis]
15 Nagengast WB, Oude Munnink TH, Dijkers EC, Hospers GA, Brouwers AH, Schröder CP, Lub-de Hooge M, de Vries EG. Multidrug resistance in oncology and beyond: from imaging of drug efflux pumps to cellular drug targets. Methods Mol Biol 2010;596:15-31. [PMID: 19949918 DOI: 10.1007/978-1-60761-416-6_2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
16 Teo KY, Han B. Freezing-Assisted Intracellular Drug Delivery to Multidrug Resistant Cancer Cells. Journal of Biomechanical Engineering 2009;131:074513. [DOI: 10.1115/1.3153325] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
17 Santisteban M, Reiman JM, Asiedu MK, Behrens MD, Nassar A, Kalli KR, Haluska P, Ingle JN, Hartmann LC, Manjili MH. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res. 2009;69:2887-2895. [PMID: 19276366 DOI: 10.1158/0008-5472.can-08-3343] [Cited by in Crossref: 299] [Cited by in F6Publishing: 313] [Article Influence: 23.0] [Reference Citation Analysis]
18 Fan D, Kim S, Langley RL, Fidler IJ. Metastasis and Drug Resistance. In: Siddik ZH, Mehta K, editors. Drug Resistance in Cancer Cells. New York: Springer US; 2009. pp. 21-52. [DOI: 10.1007/978-0-387-89445-4_2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
19 Guo X, Ma N, Wang J, Song J, Bu X, Cheng Y, Sun K, Xiong H, Jiang G, Zhang B. Increased p38-MAPK is responsible for chemotherapy resistance in human gastric cancer cells. BMC Cancer. 2008;8:375. [PMID: 19091131 DOI: 10.1186/1471-2407-8-375] [Cited by in Crossref: 90] [Cited by in F6Publishing: 95] [Article Influence: 6.4] [Reference Citation Analysis]
20 Chang H, Rha SY, Jeung HC, Im CK, Ahn JB, Kwon WS, Yoo NC, Roh JK, Chung HC. Association of the ABCB1 gene polymorphisms 2677G& gt; T/A and 3435C& gt; T with clinical outcomes of paclitaxel monotherapy in metastatic breast cancer patients. Ann Oncol. 2009;20:272-277. [PMID: 18836089 DOI: 10.1093/annonc/mdn624] [Cited by in Crossref: 79] [Cited by in F6Publishing: 87] [Article Influence: 5.6] [Reference Citation Analysis]
21 Bu LM, Sun SH, Hua JP, Han Y, Lai J, Bao WY. Preparation of HCT-8/5-fluorouracil multidrug resistant cell line and detection of P-glycoprotein. Shijie Huaren Xiaohua Zazhi 2006; 14(21): 2082-2086 [DOI: 10.11569/wcjd.v14.i21.2082] [Reference Citation Analysis]
22 Su Y, Lee SH, Sinko PJ. Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance. Eur J Pharm Sci 2006;29:102-10. [PMID: 16844360 DOI: 10.1016/j.ejps.2006.06.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]